{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:45:08Z","timestamp":1789854308982,"version":"4.0.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2006,10,30]],"date-time":"2006-10-30T00:00:00Z","timestamp":1162166400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1007\/s00787-006-0580-1","type":"journal-article","created":{"date-parts":[[2006,10,30]],"date-time":"2006-10-30T16:55:58Z","timestamp":1162227358000},"page":"104-120","source":"Crossref","is-referenced-by-count":93,"title":["Management of psychiatric disorders in children and adolescents with atypical antipsychotics"],"prefix":"10.1007","volume":"16","author":[{"given":"Peter S.","family":"Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Buitelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gahan J.","family":"Pandina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,10,30]]},"reference":[{"key":"580_CR1","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.2337\/diacare.27.7.1798","volume":"27","author":"G Alberti","year":"2004","unstructured":"Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M (2004) Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care 27:1798\u20131811","journal-title":"Diabetes Care"},{"key":"580_CR2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/104454602760219126","volume":"12","author":"CL Alfaro","year":"2002","unstructured":"Alfaro CL, Wudarksy M, Nicolson R, Gochman P, Sporn A, Lenane M et al (2002) Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol 12:83\u201391","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"580_CR3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/1044546041649020","volume":"14","author":"MG Aman","year":"2004","unstructured":"Aman MG, Binder C, Turgay A (2004) Risperidone effects in the presence\/absence of psychostimulant medication in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol 14:243\u2013254","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"580_CR4","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1176\/appi.ajp.159.8.1337","volume":"159","author":"MG Aman","year":"2002","unstructured":"Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL (2002) Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337\u20131346","journal-title":"Am J Psychiatry"},{"key":"580_CR5","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","volume":"27","author":"American Diabetes Association","year":"2004","unstructured":"American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596\u2013601","journal-title":"Diabetes Care"},{"key":"580_CR6","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders. 4edn. Washington, DC: American Psychiatric Association","edition":"4"},{"key":"580_CR7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/cap.2005.15.311","volume":"15","author":"J Biederman","year":"2005","unstructured":"Biederman J, Mick E, Wozniak J, Aleardi M, Spencer T, Faraone SV (2005) An open-label trial of risperidone in children and adolescents with biploar disorder. J Child and Adolesc Psychopharmacol 15:311\u2013317","journal-title":"J Child and Adolesc Psychopharmacol"},{"key":"580_CR8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.biopsych.2005.03.019","volume":"58","author":"J Biederman","year":"2005","unstructured":"Biederman J, Mick E, Hammerness P, Harpold T, Aleardi M, Dougherty M, Wozniak J (2005) Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry 58:589\u2013594","journal-title":"Biol Psychiatry"},{"key":"580_CR9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.chi.0000145372.61239.bb","volume":"44","author":"J Blair","year":"2005","unstructured":"Blair J, Scahill L, State M, Martin A (2005) Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry 44:73\u201379","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"580_CR10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/cap.2000.10.19","volume":"10","author":"JK Buitelaar","year":"2000","unstructured":"Buitelaar JK (2000) Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolesc Psychopharmacol 10:19\u201326","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"580_CR11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4088\/JCP.v62n0405","volume":"62","author":"Buitelaar","year":"2001","unstructured":"Buitelaar JK, van der Gaag, Cohen-Kettenis P, Melman CT (2001) A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62:239\u2013248","journal-title":"J Clin Psychiatry"},{"key":"580_CR12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","volume":"158","author":"M Chakos","year":"2001","unstructured":"Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B (2001) Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 158:518\u2013526","journal-title":"Am J Psychiatry"},{"key":"580_CR13","doi-asserted-by":"crossref","first-page":"967","DOI":"10.4088\/JCP.v62n1209","volume":"62","author":"DF Connor","year":"2001","unstructured":"Connor DF, Fletcher KE, Wood JS (2001) Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry 62:967\u2013974","journal-title":"J Clin Psychiatry"},{"key":"580_CR14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","volume":"161","author":"CU Correll","year":"2004","unstructured":"Correll CU, Leucht S, Kane JM (2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systemic review of 1-year studies. Am J Psychiatry 161:414\u2013425","journal-title":"Am J Psychiatry"},{"key":"580_CR15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.chi.0000145805.24274.09","volume":"44","author":"Croonenberghs","year":"2005","unstructured":"Croonenberghs J, Fegert JM, Findling RL, De Smedt G, Van Dongen S, and the Risperidone Disruptive Behavior Study Group (2005) J Am Acad Child Adolesc Psychiatry 44:64\u201372","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"580_CR16","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/00004583-200210000-00011","volume":"41","author":"MP Delbello","year":"2002","unstructured":"Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM (2002) A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 41:1216\u20131223","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"580_CR17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0011-393X(02)80009-1","volume":"63","author":"RS Diler","year":"2002","unstructured":"Diler RS, Firat S, Avci A (2002) An open-label trial of risperidone in children with autism. Curr Ther Res 63:91\u2013102","journal-title":"Curr Ther Res"},{"key":"580_CR18","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1176\/appi.ajp.161.5.918","volume":"161","author":"F Dunbar","year":"2004","unstructured":"Dunbar F, Daneman D (2004) Growth and sexual maturation during long term treatment with risperidone. Am J Psychiatry 161:918\u2013920","journal-title":"Am J Psychiatry"},{"key":"580_CR19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00004583-200004000-00021","volume":"39","author":"RL Findling","year":"2000","unstructured":"Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL (2000) A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39:509\u2013516","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"580_CR20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1176\/appi.ajp.161.4.677","volume":"161","author":"RL Findling","year":"2004","unstructured":"Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B (2004) Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 161:677\u2013684","journal-title":"Am J Psychiatry"},{"key":"580_CR21","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4088\/JCP.v64n1113","volume":"64","author":"RL Findling","year":"2003","unstructured":"Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt D, Binder C (2003) Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 64:1362\u20131369","journal-title":"J Clin Psychiatry"},{"key":"580_CR22","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/00004583-199908000-00011","volume":"38","author":"JA Frazier","year":"1999","unstructured":"Frazier JA, Meyer MC, Biederman J, Wozniak J, Wilens TE, Spencer TJ et al (1999) Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. J Am Acad Child Adolesc Psychiatry 38:960\u2013965","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"580_CR23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/10445460152595568","volume":"11","author":"JA Frazier","year":"2001","unstructured":"Frazier JA, Biederman J, Tohen M, Feldman PD, Jacobs TG, Toma V et al (2001) A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 11:239\u2013250","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"580_CR24","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00004583-200203000-00013","volume":"41","author":"GR Gaffney","year":"2002","unstructured":"Gaffney GR, Perry PJ, Lund BC, Bever-Stille KA, Arndt S, Kuperman S (2002) Risperidone versus clonidine in the treatment of children and adolescents with Tourette\u2019s Syndrome. J Am Acad Child Adolesc Psychiatry 41:330\u2013336","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"580_CR25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/104454604773840472","volume":"14","author":"A Gagliano","year":"2004","unstructured":"Gagliano A, Germano E, Pustorino G, Impallomeni C, D\u2019Arigo C, Calamoneri F et al (2004) Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 14:39\u201347","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"580_CR26","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1097\/01.chi.0000171904.23947.54","volume":"44","author":"G Gerbino-Rosen","year":"2005","unstructured":"Gerbino-Rosen G, Roofeh D, Tompkins DA, Feryo D, Nusser L, Kranzler H, Napolitano B, Frederickson A, Henderson I, Rhinewine J, Kumra S (2005) Hematological adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatry 44:1024\u20131031","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"580_CR27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00004583-200402000-00017","volume":"43","author":"DL Gilbert","year":"2004","unstructured":"Gilbert DL, Batterson JR, Sethuraman G, Sallee FR (2004) Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry 43:206\u2013214","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"580_CR28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00702-002-0803-7","volume":"110","author":"D Gothelf","year":"2003","unstructured":"Gothelf D, Apter A, Reidman J, Brand-Gothelf A, Bloch Y, Gal G et al (2003) Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. J Neural Transm 110:545\u2013560","journal-title":"J Neural Transm"},{"key":"580_CR29","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1176\/appi.ajp.159.7.1214","volume":"159","author":"RW Greene","year":"2002","unstructured":"Greene RW, Biederman J, Zerwas S, Monuteaux MC, Goring JC, Faraone SV (2002) Psychiatric comorbidity, family dysfunction, and social impairment in referred youth with oppositional defiant disorder. Am J Psychiatry 159:1214\u20131224","journal-title":"Am J Psychiatry"},{"key":"580_CR30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/10445460152595559","volume":"11","author":"JA Hellings","year":"2001","unstructured":"Hellings JA, Zarcone JR, Crandall K, Wallace D, Schroeder SR (2001) Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 11:229\u2013238","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"580_CR31","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1023\/A:1025058711465","volume":"33","author":"K Jarbrink","year":"2003","unstructured":"Jarbrink K, Fombonne E, Knapp M (2003) Measuring the parental, service and cost impacts of children with autistic spectrum disorder: a pilot study. J Autism Develop Disord 33:395\u2013402","journal-title":"J Autism Develop Disord"},{"key":"580_CR32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/cap.1998.8.151","volume":"8","author":"DL Kelly","year":"1998","unstructured":"Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM (1998) Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 8:151\u2013159","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"580_CR33","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00004714-200210000-00003","volume":"22","author":"C Kemner","year":"2002","unstructured":"Kemner C, Willemsen-Swinkels SN, de Jonge M, Tuynman-Qua H, van Engeland H (2002) Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 22:455\u2013460","journal-title":"J Clin Psychopharmacol"},{"key":"580_CR34","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1001\/jama.286.20.2542","volume":"286","author":"E Koller","year":"2001","unstructured":"Koller E, Malozowski S, Doraiswamy PM (2001) Atypical antipsychotic drugs and hyperglycemia in adolescents. JAMA 286:2547\u20132548","journal-title":"JAMA"},{"key":"580_CR35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1542\/peds.113.2.421","volume":"113","author":"EA Koller","year":"2004","unstructured":"Koller EA, Cross JT, Schneider B (2004) Risperidone-associated diabetes mellitus in children. Pediatrics 113:421\u2013422 (author reply 421\u2013422)","journal-title":"Pediatrics"},{"key":"580_CR36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/01.chi.0000145371.23122.5a","volume":"44","author":"H Kranzler","year":"2005","unstructured":"Kranzler H, Roofeh D, Gerbino-Rosen G, Dombrowski C, McMeniman M, DeThomas C, Frederickson A, Nusser L, Bienstock MD, Fisch GS, Kumra S (2005) Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 44:55\u201363","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"580_CR37","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1001\/archpsyc.1996.01830120020005","volume":"53","author":"S Kumra","year":"1996","unstructured":"Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC et al (1996) Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 53:1090\u20131097","journal-title":"Arch Gen Psychiatry"},{"key":"580_CR38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0924-977X(03)00045-2","volume":"14","author":"S Kutcher","year":"2004","unstructured":"Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J et al (2004) International consensus statement on attention-deficit\/hyperactivity disorder (ADHD) and disruptive behavior disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 14:11\u201328","journal-title":"Eur Neuropsychopharmacol"},{"key":"580_CR39","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/070674379804300608","volume":"43","author":"R Lewis","year":"1998","unstructured":"Lewis R (1998) Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Can J Psychiatry 43:596\u2013604","journal-title":"Can J Psychiatry"},{"issue":"Suppl 23","key":"580_CR40","first-page":"30","volume":"62","author":"JP Lindenmayer","year":"2001","unstructured":"Lindenmayer JP, Nathan AM, Smith RC (2001) Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 62(Suppl 23):30\u201338","journal-title":"J Clin Psychiatry"},{"key":"580_CR41","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/000992280404300504","volume":"43","author":"RL Lindsay","year":"2004","unstructured":"Lindsay RL, Leone S, Aman MG (2004) Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders. Clin Pediatr 43:437\u2013444","journal-title":"Clin Pediatr"},{"key":"580_CR42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00004583-200202000-00007","volume":"41","author":"RP Malone","year":"2002","unstructured":"Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA (2002) Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 41:140\u2013147","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"580_CR43","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.161.6.1125","volume":"161","author":"A Martin","year":"2004","unstructured":"Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J et al (2004) Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 161:1125\u20131127","journal-title":"Am J Psychiatry"},{"key":"580_CR44","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1097\/00004583-200110000-00015","volume":"40","author":"G Masi","year":"2001","unstructured":"Masi G, Cosenza A, Mucci M, Brovedani P (2001) Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 40:1206\u20131214","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"580_CR45","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","volume":"347","author":"JT McCracken","year":"2002","unstructured":"McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG et al (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314\u2013321","journal-title":"N Engl J Med"},{"key":"580_CR46","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","volume":"162","author":"CJ McDougle","year":"2005","unstructured":"McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, Shah B, Chuang SZ, Swiezy NB, Gonzalez NM, Hollway J, Koenig K, McGough JJ, Ritz L, Vitiello B (2005) Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. Am J Psychiatry 162:1142\u20131148","journal-title":"Am J Psychiatry"},{"key":"580_CR47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","volume":"25","author":"HY Meltzer","year":"1999","unstructured":"Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233\u2013255","journal-title":"Schizophr Bull"},{"key":"580_CR48","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00004583-200302000-00008","volume":"42","author":"E Pappadopulos","year":"2003","unstructured":"Pappadopulos E, MacIntyre JC, Crimson ML, Findling RL, Malone RP, Derivan A et al (2003) Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry 42:145\u2013161","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"Suppl 1","key":"580_CR49","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.jad.2004.05.017","volume":"82","author":"MN Pavuluri","year":"2004","unstructured":"Pavuluri MN, Henry DB, Carbray JA, Samson G, Naylor MW, Janicak PG (2004) Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. J Affect Disord 82(Suppl 1):S103\u2013S111","journal-title":"J Affect Disord"},{"key":"580_CR50","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00004583-200203000-00014","volume":"41","author":"G Ratzoni","year":"2002","unstructured":"Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G et al (2002) Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 41:337\u2013343","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"580_CR51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s702-002-8240-3","volume":"109","author":"H Remschmidt","year":"2002","unstructured":"Remschmidt H (2002) Early-onset schizophrenia as a progressive-deteriorating developmental disorder: evidence from child psychiatry. J Neural Transm 109:101\u2013117","journal-title":"J Neural Transm"},{"key":"580_CR52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s007870070015","volume":"9","author":"H Remschmidt","year":"2000","unstructured":"Remschmidt H, Hennighausen K, Clement HW, Heiser P, Schulz E (2000) Atypical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry 9:9\u201319","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"580_CR53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/cap.1994.4.31","volume":"4","author":"H Remschmidt","year":"1994","unstructured":"Remschmidt H, Schulz E, Martin PM (1994) An open trial of clozapine in thirty-six adolescents with schizophrenia. J Child Adolesc Psychopharmacol 4:31\u201341","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"580_CR54","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/00004583-199707000-00023","volume":"36","author":"AG Renouf","year":"1997","unstructured":"Renouf AG, Kovacs M, Mukerji P (1997) Relationship of depressive, conduct, and comorbid disorders and social functioning in childhood. J Am Acad Child Adolesc Psychiatry 36:998\u20131004","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"580_CR55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00787-006-0504-0","volume":"15","author":"M Reyes","year":"2006","unstructured":"Reyes M, Olah R, Csaba K, Augustyns I, Eerdekens M (2006) Long-term safety and efficacy of risperidone in children with disruptive behaviour disorder: Results of a 2-year extensive study. Eur Child and Adolesc Psychiatry 15:97\u2013104","journal-title":"Eur Child and Adolesc Psychiatry"},{"key":"580_CR56","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1176\/appi.ajp.163.3.402","volume":"163","author":"M Reyes","year":"2006","unstructured":"Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M (2006) A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 163:402\u2013410","journal-title":"Am J Psychiatry"},{"key":"580_CR57","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/104454603322572633","volume":"13","author":"RG Ross","year":"2003","unstructured":"Ross RG, Novins D, Farley GK, Adler LE (2003) A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol 13:301\u2013309","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"580_CR58","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","volume":"162","author":"RUPP","year":"2005","unstructured":"RUPP (Research Units on Pediatric Psychopharmacology) Autism Network (2005) Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6\u00a0months. Am J Psychiatry 162:1361\u20131369","journal-title":"Am J Psychiatry"},{"key":"580_CR59","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","volume":"39","author":"FR Sallee","year":"2000","unstructured":"Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G et al (2000) Ziprasidone treatment of children and adolescents with Tourette\u2019s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 39:292\u2013299","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"580_CR60","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","volume":"60","author":"L Scahill","year":"2003","unstructured":"Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS (2003) A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 60:1130\u20131135","journal-title":"Neurology"},{"key":"580_CR61","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/bmj.323.7306.191","volume":"323","author":"S Scott","year":"2001","unstructured":"Scott S, Knapp M, Henderson J, Maughan B (2001) Financial cost of social exclusion: follow up study of antisocial children into adulthood. BMJ 323:191\u2013193","journal-title":"BMJ"},{"key":"580_CR62","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","volume":"114","author":"S Shea","year":"2004","unstructured":"Shea S, Turgay A, Carroll A, Shulz M, Orlik H, Smith I, Dunbar F (2004) Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114:e634\u2013e641","journal-title":"Pediatrics"},{"key":"580_CR63","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.npp.1300327","volume":"29","author":"L Sikich","year":"2004","unstructured":"Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA (2004) A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 29:133\u2013145","journal-title":"Neuropsychopharmacology"},{"key":"580_CR64","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/00004583-200209000-00002","volume":"41","author":"R Snyder","year":"2002","unstructured":"Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A (2002) Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026\u20131036","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"580_CR65","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s00787-002-0265-3","volume":"11","author":"H Soderstrom","year":"2002","unstructured":"Soderstrom H, Rastam M, Gillberg C (2002) A clinical case series of six extremely aggressive youths treated with olanzapine. Eur Child Adolesc Psychiatry 11:138\u2013141","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"580_CR66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00148581-200406010-00003","volume":"6","author":"KA Stigler","year":"2004","unstructured":"Stigler KA, Potenza MN, Posey DJ, McDougle CJ (2004) Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. Paediatr Drugs 6:33\u201344","journal-title":"Paediatr Drugs"},{"key":"580_CR67","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/01.chi.0000177055.11229.76","volume":"44","author":"PW Troost","year":"2005","unstructured":"Troost PW, Lahuis BE, Steenhuis MP, Ketelaars CE, Buitelaar JK, van Engeland H, Scahill L, Minderaa RB, Hoekstra PJ (2005) Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 44:1137\u20131144","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"580_CR68","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1542\/peds.110.3.e34","volume":"110","author":"A Turgay","year":"2002","unstructured":"Turgay A, Binder C, Snyder R, Fisman S (2002) Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110:e34","journal-title":"Pediatrics"},{"key":"580_CR69","first-page":"5","volume":"11","author":"M Bellinghen van","year":"2001","unstructured":"van Bellinghen M, de Troch C (2001) Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychiatry 11:5\u201313","journal-title":"J Child Adolesc Psychiatry"},{"key":"580_CR70","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/cap.1999.9.239","volume":"9","author":"M Wudarksy","year":"1999","unstructured":"Wudarksy M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J et al (1999) Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 9:239\u2013245","journal-title":"J Child Adolesc Psychopharmacol"}],"container-title":["European Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-006-0580-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00787-006-0580-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-006-0580-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T06:33:21Z","timestamp":1559111601000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00787-006-0580-1"}},"subtitle":["A systematic review of published clinical trials"],"short-title":[],"issued":{"date-parts":[[2006,10,30]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["580"],"URL":"https:\/\/doi.org\/10.1007\/s00787-006-0580-1","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"value":"1018-8827","type":"print"},{"value":"1435-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,30]]}}}